Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

If you may have missed any crucial approvals or updates last month, this article provides a brief description of each FDA action and a link to the initial coverage ... Breast06 [NCT04494425] show that ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

These innovative therapies consist of an antibody linked to a cytotoxic agent through a stable linker, allowing targeted delivery ... Among these, prominent examples include Padcev, Kadcyla, and ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

My déjà vu was triggered by the Access to Medicines Foundation, which reported that, although many pharma companies have programmes to improve access to medicines in low- to middle-income countries, ...

Trodelvy shows consistent efficacy in metastatic triple-negative breast cancer with a 27.8% ORR and 4.8 months PFS. Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving ...

Tanya Gupta, MD, medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology, evaluates fam-trastuzumab deruxtecan-nxki (Enhertu ... and it is bound by a linker ...